Overview

Description

  • NatureSynthetic
  • Amino Acid Sequence 1
    • SpeciesHuman
    • SequenceCGG-DPEAAE
    • Amino acids436 to 441
    Amino Acid Sequence 2
    • SpeciesHuman
    • SequenceCGG-DPEAAE
    • Amino acids436 to 441

Associated products

Specifications

Our Abpromise guarantee covers the use of ab39784 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Applications

    Blocking - Blocking peptide for Anti-Versican antibody (ab19345)

    Neutralising

  • Purity> 90 % SDS-PAGE.
    This peptide is greater than 70% pure.
  • FormLiquid
  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.

    Double distilled water or equivalent after reconstitution.

General Info

  • Alternative names
    • Chondroitin sulfate proteoglycan 2
    • Chondroitin sulfate proteoglycan core protein 2
    • Chondroitin sulfate proteoglycan core protein, cartilage
    • CSPG2
    • CSPG2_HUMAN
    • ERVR
    • GHAP
    • Glial hyaluronate binding protein
    • Glial hyaluronate-binding protein
    • Large fibroblast proteoglycan
    • PG-M
    • PGM
    • VCAN
    • Versican
    • Versican core protein
    • Versican proteoglycan
    • WGN
    • WGN 1
    • WGN1
    see all
  • FunctionMay play a role in intercellular signaling and in connecting cells with the extracellular matrix. May take part in the regulation of cell motility, growth and differentiation. Binds hyaluronic acid.
  • Tissue specificityCerebral white matter and plasma. Isoform V0 and isoform V1 are expressed in normal brain, gliomas, medulloblastomas, schwannomas, neurofibromas, and meningiomas. Isoform V2 is restricted to normal brain and gliomas. Isoform V3 is found in all these tissues except medulloblastomas.
  • Involvement in diseaseDefects in VCAN are the cause of Wagner syndrome type 1 (WGN1) [MIM:143200]. WGN is a dominantly inherited vitreoretinopathy characterized by an optically empty vitreous cavity with fibrillary condensations and a preretinal avascular membrane. Other optical features include progressive chorioretinal atrophy, perivascular sheating, subcapsular cataract and myopia. Systemic manifestations are absent in WGN.
  • Sequence similaritiesBelongs to the aggrecan/versican proteoglycan family.
    Contains 1 C-type lectin domain.
    Contains 2 EGF-like domains.
    Contains 1 Ig-like V-type (immunoglobulin-like) domain.
    Contains 2 Link domains.
    Contains 1 Sushi (CCP/SCR) domain.
  • Developmental stageDisappears after the cartilage development.
  • Post-translational
    modifications
    Phosphorylation sites are present in the extracelllular medium.
  • Cellular localizationSecreted > extracellular space > extracellular matrix.
  • Information by UniProt

References for Human Versican peptide (ab39784)

ab39784 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab39784.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"